Nextmune, Through Spectrum Veterinary, Acquires U.S. Veterinary Allergy Testing and Treatment Activities From ALK
October 22 2019 - 12:14PM
Business Wire
Nextmune, the global leader in companion-animal allergy testing
and treatment, based in Sweden, has agreed to acquire the U.S.
veterinary business activities known as ACTT from ALK, a global,
research-driven pharmaceutical company that focuses on prevention,
diagnosis, and treatment of allergies. The acquisition will be made
through Nextmune’s wholly owned subsidiary Spectrum Veterinary, LLC
in Phoenix, Arizona. Spectrum Veterinary and ACTT are diagnostic
laboratory and pharmaceutical companies that specialize in allergy
diagnosis and treatment through general and dermatological
veterinary practices. ALK’s veterinary line of in-vitro testing and
immunotherapy treatment sets, known as ACTT, and veterinary
allergenic extracts, will transition to Spectrum Veterinary as part
of this transaction. ALK will be focusing solely on human health
going forward.
The value of the transaction was not disclosed; it is expected
to close by the end of November 2019.
Magnus Kjellberg, president and CEO of Nextmune, said: “We are
shaping the future of pet allergy management. Over the past few
years, we have built up a global number-one position in allergy
testing and treatment for dogs, cats, and horses. Today, our
presence spans more than 70 countries served from GMP- and
USDA-licensed laboratories in Europe and the U.S. Our ambition is
to be at the forefront of science as exemplified by our Artuvetrin
serum testing and treatment, the only licensed allergy
immunotherapy in Europe, and our SPOT Platinum test franchises. We
are delighted to step-up our efforts in the U.S. and welcome ACTT’s
clients onboard.”
Megan Spencer, director of Sales of Spectrum Veterinary, said:
“Spectrum Veterinary has been the leader in allergy testing and
treatment in the U.S. for more than 30 years. We understand our
veterinarian clients and their pet-owner clients, and we provide a
vital service that improves the lives of animals who suffer. This
transaction further cements that leadership position and ensures
our ability to continue to invest in providing state-of-the art
services and solutions.”
Under the terms of the agreement, ALK will fully exit the U.S.
veterinary-allergy testing and treatment business, giving Spectrum
Veterinary the right and access to earn the business of ALK’s
current general veterinary and veterinary dermatology clients. As
part of the transaction, Spectrum Veterinary will have exclusive
rights to the allergen extracts manufactured by ALK that are now
sold in bulk to veterinary dermatologists. These allergens are used
by dermatologists to test for allergies and to treat allergic
conditions in pets.
Jorge Alderete, president of ALK-Abello, Inc. North America,
explained: “We are delighted to find a home with the U.S. market
leader for ACTT and for ALK’s bulk allergens for veterinary
clients. Our sole focus will be on identifying innovative
treatments for human allergy going forward. Spectrum Veterinary
will enhance the value they provide to the veterinary market with
its focus and leadership in the veterinary space. I am convinced
that our clients will be well taken care of. ALK will assist
Spectrum Veterinary with its knowledge of bulk allergenic extracts
to ensure our expertise in allergenic technology continues to be
available to veterinary dermatology specialists.”
Spencer added: “We are working closely with our colleagues at
ALK to ensure that veterinarians and pet owners will make the
transition to Spectrum Veterinary seamlessly. At the same time,
they’ll enjoy the benefits that have earned accolades from Spectrum
Veterinary’s clients. These include ease of submitting samples,
industry-leading turnaround time, and our patented SPOT Platinum
test, which is the standard for serum allergy testing in the U.S.
Both veterinarians and pet owners appreciate our
pet-owner-friendly, customized results and recommendations reports
that help veterinarians explain test results and treatment.”
For testing forms, samples of patient education and support
materials, and information about testing methods, visit
www.Spectrum.vet or call 1-877-721-5316.
About Nextmune
Nextmune is a science-driven, global specialty pharmaceutical
company dedicated to better health for dogs, cats, and horses. We
have a particular passion for allergy prevention, diagnosis, and
treatment. Our business is at the forefront of allergy diagnostics
and immunotherapy—a unique treatment that reduces or eliminates
allergic symptoms by fighting the cause of allergy. It is the first
choice for treating allergies. Find more at www.nextmune.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191022005987/en/
Spectrum Veterinary Megan Spencer Sales Director
mspencer@vetallergy.com Phone 877-721-5316
Public Relations Firm David Kirk thePRguy LLC
DavidKirk@thePRguy.com Phone 480-270-9631